Drug resistant breast cancer cells overexpress ETS1 gene

Biomedicine and Pharmacotherapy

Volumn 64, Issue 7, 2010, Pages 458-462

  Kars, Meltem Demirel ^a   Işeri, Özlem Darcansoy ^a,b   Gündüz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

ETS1; Matrix metalloproteinases; MCF 7; MDR1; Microarray analysis

Indexed keywords

DOCETAXEL; DOXORUBICIN; GELATINASE B; INTERSTITIAL COLLAGENASE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; RNA; VINCRISTINE;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; COMPUTER PROGRAM; CONTROLLED STUDY; ETS1 GENE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MICROARRAY ANALYSIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; MATRIX METALLOPROTEINASE 1; ONCOGENES; PACLITAXEL; PROTO-ONCOGENE PROTEIN C-ETS-1; TAXOIDS; VINCRISTINE;

EID: 77956448047     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.01.008     Document Type: Article

References (39)

1. Deuchars K.L., Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989, 16:156-165.
2. Roninson I.B. Tumor senescence as a determinant of drug response in vivo. Drug Resist Update 2002, 5:204-208.
3. Zaffaroni N., Daidone M.G. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002, 5:65-72.
4. Broxterman H.J., Lankelma J., Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist Updat 2003, 6:111-127.
5. Young A.M., Allen C.E., Audus K.L. Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003, 55:125-132.
6. Dittmer D., Pati S., Zambetti G., et al. Gain of function mutations in p53. Nat Genet 1993, 4:42-46.
7. Somerville R.P.T., Oblander S.A., Apte S.S. Matrix metalloproteinases: old dogs with new tricks. Genome Biol 2003, 4(6). [Article 216].
8. Sampath J., Sun D., Kidd V.J., et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001, 276:39359-39367.
9. Vogelstein B., Kinzler K.W. Colorectal cancer and the intersection between basic and clinical research. Cold Spring Harb Symp Quant Biol 1994, 59:517-521.
10. Powell B., Soong R., Iacopetta B., et al. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 2000, 6(2):443-541.
11. Zhou W, Muggerud AA, Vu P, et al. Full sequencing of TP53 identify identical mutations in situ and invasive components in breast cancer suggesting clonal evolution. Mol Oncol 2009; doi:10.1016/j.molonc.2009.03.001.
12. Aaas T., Borresen A.L., Geisler S., et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breat cancer patients. Nat Med 1996, 2(7):811-814.
13. Borresen-Dale A.L. TP53 and breast cancer. Hum Mutat 2003, 21:292-300.
14. Borresen-Dale A.L., Andersen T.I., Eyfjord J.E., Cornelis R.S., Thorlacius S., Hartman S. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc binding domains. Genes Chromosomes Cancer 1995, 14(1):71-75.
15. Oliver M., Langerod A., Carrieri P., et al. The clinical value of somatic TP53 mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006, 12(4):1157-1167.
16. Li Z.W., Dalton W.S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 2006, 20:333-342.
17. Menzel T., Rahman Z., Calleja E., et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996, 87(3):1056-1063.
18. König A., Menzel T., Lynen S., et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997, 11(2):258-265.
19. Oda N., Abe M., Sato Y. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J Cell Physiol 1999, 178(2):121-132.
20. Kars M.D., Işeri O.D., Gunduz U., Molnar J. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy 2008, 54:194-200.
21. Işeri O.D., Kars M.D., Eroĝlu S., Gündüz U. Drug resistant MCF-7 cell lines also developed cross-resistance to structurally unrelated anticancer agents. Int J Hematol Oncol 2009, 19(1):1-8.
22. Işeri OD, Kars MD, Arpaci F, Gündüz U. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol 2009; doi:10.1007/s00280-009-1048-z.
23. Yilmaz R., Yücel M., Öktem H.A. Quality assessment of gene expression data for an affymetrix platform with the two sample t-tests statistical analysis. Int J Biotech Biochem 2008, 4:101-108.
24. Kars MD, İşeri ÖD, Ural AU, et al. Development of radioresistance in drug resistant human MCF-7 breast cancer cells. J Radiother Pract 2009;8:207-13.
25. Sato Y., Abe M., Tanaka K., Iwasaka C., et al. Signal transduction and transcriptional regulation of angiogenesis. Adv Exp Med Biol 2000, 476:109-115.
26. Jiang Y., Wang M., Celiker M.Y., et al. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001, 61(6):2365-2370.
27. Turner D.P., Findlay V.J., Moussa O., Watson D.K. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J Cell Biochem 2007, 102:549-559.
28. Buggy Y., Maguire T.M., McGreal G., et al. Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer 2004, 91:1308-1315.
29. Seth A., Watson D.K. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005, 41:2462-2478.
30. Alkhalaf M., El-Mowafy A.M. Overexpression of wild-type p53 gene renders MCF-7 breast cancer cells more sensitive to the antiproliferative effect of progesterone. J Endocrinol 2003, 179:55-62.
31. Olivier M., Hainaut P. Tp53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol 2001, 11:353-360.
32. dit Faute M.A., Laurent L., Ploton D., Poupon M.F., Jardillier J.C., Bobichon H. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis 2002, 19:161-168.
33. Hart A.H., Reventar R., Bernstein A. Genetic analysis of ETS genes in C. elegans. Oncogene 2000, 19:6400-6408.
34. Macleod K., Leprince D., Stehelin D. The ets gene family. Trends Biochem Sci 1992, 17:251-256.
35. Lindemann R.K., Nordheim A., Dittmer J. Interfering with TGF beta-induced Smad3 nuclear accumulation differentially affects TGFbeta-dependent gene expression. Mol Cancer 2003, 2:20.
36. Shih S.C., Claffey K.P. Role of AP-1 and HIF-1 transcription factors in TGF-b activation of VEGF expression. Growth Factors 2001, 19:19-34.
37. Behrens P., Rothe M., Wellmann A., Krischler J., Wernert N. The ETS-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol 2001, 194:43-50.
38. Fujimoto J., Aoki I., Toyoki H., Khatun S., Tamaya T. Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers. Ann Oncol 2002, 13:1598-1604.
39. Kitange G., Tsunoda K., Anda T., et al. Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas. Cancer 2000, 89:2292-2300.